NDMA is a cancer-causing human carcinogen. It is dangerous and high levels should be avoided. In 2019, the FDA became aware of NDMA in ranitidine and in September of 2019 they started to warn the public of the potential risks.
This has caused a stream of lawsuits against the manufacturers, Sanofi and Boerhringer Ingelheim which allege that the manufacturers were responsible for placing a product on the market that was contaminated with a known carcinogenic agent.
One of the first Zantac lawsuits was initiated in California in 2019 against Sanofi and Boerhringer Ingelheim. The allegations involve that the makers of Zantac were aware (or could reasonably be expected to be aware) of the risk that their products could pose to users and they failed to disclose this known risk to consumers and the government.
Thereafter, several lawsuits were filed against Sanofi and Boerhringer Ingelheim around the country. The judicial panel of multidistrict litigation (JPML) has since consolidated all litigation against the makers of Zantac in federal court in the Southern District of Florida. The proceedings are taking place in front of Judge Robin L. Rosenberg under multidistrict litigation (MDL) 2924.